Ivan P. Gergel - Net Worth and Insider Trading

Ivan P. Gergel Net Worth

The estimated net worth of Ivan P. Gergel is at least $56,542 dollars as of 2024-04-25. Ivan P. Gergel is the SVP & Chief Medical Officer of Nektar Therapeutics and owns about 41,575 shares of Nektar Therapeutics (NKTR) stock worth over $56,542. Ivan P. Gergel is also the EVP, R&D and CSO of Endo International PLC and owns about 27,649 shares of Endo International PLC (ENDPQ) stock worth over $0. Details can be seen in Ivan P. Gergel's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Ivan P. Gergel has not made any transactions after 2017-10-02 and currently still holds the listed stock(s).

Transaction Summary of Ivan P. Gergel

Ivan P. Gergel Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Ivan P. Gergel owns 4 companies in total, including Neurotrope Inc (NTRP) , Corium International Inc (CORI) , and Nektar Therapeutics (NKTR) among others .

Click here to see the complete history of Ivan P. Gergel’s form 4 insider trades.

Insider Ownership Summary of Ivan P. Gergel

Ticker	Comapny	Transaction Date	Type of Owner
NTRP	Neurotrope Inc	2020-03-20	director
CORI	Corium International Inc	2018-11-27	director
NKTR	Nektar Therapeutics	2017-10-02	SVP Drug Development & CMO
ENDPQ	Endo International PLC	2014-03-10	EVP & R&D and CSO

Ivan P. Gergel Latest Holdings Summary

Ivan P. Gergel currently owns a total of 2 stocks. Among these stocks, Ivan P. Gergel owns 41,575 shares of Nektar Therapeutics (NKTR) as of October 2, 2017, with a value of $56,542 and a weighting of 100%. Ivan P. Gergel also owns 27,649 shares of Endo International PLC (ENDPQ) as of March 10, 2014, with a value of $0 and a weighting of 0%.

Latest Holdings of Ivan P. Gergel

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
NKTR	Nektar Therapeutics	2017-10-02	41,575	1.36	56,542
ENDPQ	Endo International PLC	2014-03-10	27,649	0.00	0

Holding Weightings of Ivan P. Gergel

Ivan P. Gergel Form 4 Trading Tracker

According to the SEC Form 4 filings, Ivan P. Gergel has made a total of 0 transactions in Nektar Therapeutics (NKTR) over the past 5 years. The most-recent trade in Nektar Therapeutics is the sale of 100,000 shares on October 2, 2017, which brought Ivan P. Gergel around $2 Million.

According to the SEC Form 4 filings, Ivan P. Gergel has made a total of 0 transactions in Endo International PLC (ENDPQ) over the past 5 years. The most-recent trade in Endo International PLC is the sale of 75,637 shares on March 10, 2014, which brought Ivan P. Gergel around $5 Million.

Insider Trading History of Ivan P. Gergel

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Ivan P. Gergel Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Ivan P. Gergel Ownership Network

Ownership Network List of Ivan P. Gergel

No Data

Ownership Network Relation of Ivan P. Gergel

Ivan P. Gergel Owned Company Details

What does Neurotrope Inc do?

Who are the key executives at Neurotrope Inc?

Ivan P. Gergel is the director of Neurotrope Inc. Other key executives at Neurotrope Inc include director & Chief Executive Officer Charles S. Ryan , COO and General Counsel Michael Ciraolo , and See Remarks Robert Weinstein .

Neurotrope Inc (NTRP) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Neurotrope Inc (NTRP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Neurotrope Inc (NTRP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Neurotrope Inc (NTRP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Neurotrope Inc Insider Transactions

No Available Data

What does Corium International Inc do?

Who are the key executives at Corium International Inc?

Ivan P. Gergel is the director of Corium International Inc. Other key executives at Corium International Inc include 10 percent owner Broadfin Healthcare Master Fund Ltd , 10 percent owner Broadfin Capital, Llc , and 10 percent owner Kevin Kotler .

Corium International Inc (CORI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Corium International Inc (CORI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Corium International Inc (CORI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Corium International Inc (CORI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Corium International Inc Insider Transactions

No Available Data

What does Nektar Therapeutics do?

Who are the key executives at Nektar Therapeutics?

Ivan P. Gergel is the SVP Drug Development & CMO of Nektar Therapeutics. Other key executives at Nektar Therapeutics include SVP & General Counsel Mark Andrew Wilson , Chief R&D Officer Jonathan Zalevsky , and director & President & CEO Howard W Robin .

Nektar Therapeutics (NKTR) Insider Trades Summary

Over the past 18 months, Ivan P. Gergel made no insider transaction in Nektar Therapeutics (NKTR). Other recent insider transactions involving Nektar Therapeutics (NKTR) include a net sale of 137,918 shares made by Howard W Robin , a net sale of 62,098 shares made by Jonathan Zalevsky , and a net sale of 46,514 shares made by Mark Andrew Wilson .

In summary, during the past 3 months, insiders sold 36,653 shares of Nektar Therapeutics (NKTR) in total and bought 0 shares, with a net sale of 36,653 shares. During the past 18 months, 276,610 shares of Nektar Therapeutics (NKTR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 276,610 shares.

Nektar Therapeutics (NKTR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Nektar Therapeutics Insider Transactions

No Available Data

What does Endo International PLC do?

Who are the key executives at Endo International PLC?

Ivan P. Gergel is the EVP & R&D and CSO of Endo International PLC. Other key executives at Endo International PLC include Executive VP & Global R&D James Patrick Tursi , VP & Controller and CAO Frank B. Raciti , and EVP & Head of Global R&D George Apostol .

Endo International PLC (ENDPQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Endo International PLC (ENDPQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Endo International PLC (ENDPQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Endo International PLC (ENDPQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Endo International PLC Insider Transactions

No Available Data

Ivan P. Gergel Mailing Address

Above is the net worth, insider trading, and ownership report for Ivan P. Gergel. You might contact Ivan P. Gergel via mailing address: C/o Nektar Therapeutics, 455 Mission Bay Blvd South, San Francisco Ca 94158.

Discussions on Ivan P. Gergel

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.